← Back to Search

Mirikizumab for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose up to 85 days postdose
Awards & highlights

Study Summary

This trial will compare the amount of mirikizumab in the blood stream when given via autoinjector to the reference solution given via autoinjector, as well as adverse effects and tolerability.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose up to 85 days postdose
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose up to 85 days postdose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Mirikizumab
PK: Area Under the Concentration Versus Time Curve from Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Mirikizumab
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab

Trial Design

2Treatment groups
Experimental Treatment
Group I: Mirikizumab Solution (Test)Experimental Treatment1 Intervention
Mirikizumab administered SC via an AI at 3 different injection sites (arm, thigh, and abdomen).
Group II: Mirikizumab Solution (Reference)Experimental Treatment1 Intervention
Mirikizumab administered subcutaneously (SC) via an autoinjector (AI) at 3 different injection sites (arm, thigh, and abdomen).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mirikizumab
2020
Completed Phase 3
~4790

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,618 Previous Clinical Trials
3,201,164 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,347 Previous Clinical Trials
405,358 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Mirikizumab a safe option for those seeking medical treatment?

"Based on the limited evidence available, our team at Power assigned Mirikizumab a safety score of 1. This assessment was made due to this being an early phase trial and the lack of data regarding efficacy or safety."

Answered by AI

Are there numerous venues offering this trial in the United States?

"This trial is currently being conducted in 7 distinct locations, including Cypress, Dilworth and Daytona Beach. Patients are encouraged to select the local site closest to them in order to minimize their commute should they decide to take part."

Answered by AI

Could I be considered a candidate for this medical study?

"Participants of this clinical trial should be healthy and between the ages of 18 to 65. A total of 396 volunteers are required for successful completion."

Answered by AI

Is this clinical trial open to individuals aged 85 and above?

"This medical trial is available to adults aged 18-65. For those under the age of 18, there are 50 studies that may be suitable and for those over 65, 373 trials have been posted."

Answered by AI

Is the application process for this trial still active?

"From the data present on clinicaltrials.gov, this specific study is not presently accepting patients; its original posting was August 31st 2022 and it had its last update November 22nd 2022. Despite that, there are still 841 other trials actively recruiting participants at the time of writing."

Answered by AI

Who else is applying?

What state do they live in?
New Mexico
Wisconsin
Other
Florida
How old are they?
18 - 65
What site did they apply to?
LabCorp CRU, Inc.
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0
Recent research and studies
clinicaltrials.govStudy
A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants
2022. "A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05515601.
All > Fargo
~153 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top